Fate Therapeutics Inc
General ticker "FATE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $275.3M
Fate Therapeutics Inc does not follow the US Stock Market performance with the rate: -18.4%.
Estimated limits based on current volatility of 4.6%: low 1.59$, high 1.74$
Factors to consider:
- Current price 17.4% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [2.01$, 5.81$]
- 2024-12-30 to 2025-12-30 estimated range: [3.16$, 7.88$]
Financial Metrics affecting the FATE estimates:
- Negative: Non-GAAP EPS, $ of -1.64 <= 0.10
- Negative: Operating profit margin, % of -74.99 <= 1.03
- Negative: Operating cash flow per share per price, % of -32.80 <= 2.35
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term FATE quotes
Long-term FATE plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $55.85MM | $96.30MM | $63.53MM |
| Operating Expenses | $272.84MM | $404.69MM | $254.04MM |
| Operating Income | $-216.99MM | $-308.39MM | $-190.51MM |
| Non-Operating Income | $4.84MM | $26.66MM | $29.58MM |
| Interest Expense | $0.00MM | $5.84MM | $0.00MM |
| R&D Expense | $215.52MM | $320.45MM | $172.60MM |
| Income(Loss) | $-212.15MM | $-281.72MM | $-160.93MM |
| Profit(Loss) | $-212.15MM | $-281.72MM | $-160.93MM |
| Stockholders Equity | $678.84MM | $483.94MM | $368.42MM |
| Inventory | $0.00MM | $0.00MM | $0.00MM |
| Assets | $921.46MM | $705.56MM | $506.22MM |
| Operating Cash Flow | $-162.87MM | $-248.21MM | $-132.26MM |
| Capital expenditure | $50.70MM | $35.57MM | $6.15MM |
| Investing Cash Flow | $-324.02MM | $166.75MM | $112.67MM |
| Financing Cash Flow | $453.13MM | $9.21MM | $0.09MM |
| Earnings Per Share* | $-2.18 | $-2.63 | $-1.64 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.